Author Archives: admin


O-Shot Therapy Raises Hope of Enhanced Sexual Experience in Genitally Mutilated Females – THISDAY Newspapers

Mary Nnah

There is hope for full conjugal experience with their partners for over 20 million Nigerian girls and women who have undergone female genital mutilation (FGM) with O-Shot therapy.

O-Shot, a regenerative medicine procedure that is done through Adult Stem Cell Therapy (non-invasive) or Platelet Rich Plasma (PRP) therapy (non-invasive) is a cosmetic procedure to enhance female sexual wellness.

According to Dr. David Ikudayisi, Medical Director of Glory Wellness and Regenerative Centre, Lekki, Lagos, O-Shot (aka orgasm shot) treatment, Involves injecting the Clitoris, Labia and G-spot with Platelets-substances in your blood that contains healing proteins called growth factor-extracted from your own blood.

Speaking during a recent webinar titled: Female Genital Mutilation (FGM): How to Enhance Your Sexual Experience Through Adult Stem Cell as part of the activities to mark the International Women Day, 2022, Dr. Ikudayisi explained: We use Platelet Rich Plasma (PRP) from your own blood, in addition to the use of Adult Stem Cells (such as Umbilical Blood Stem Cells, Fat-derived Stem Cells, Bone Marrow Stem Cells, Stem Cells Exosomes) and Shockwave Therapy to enhance female sexual wellness.

Ikudayisi, who is United States of America Board Certified Internist and Regenerative Medicine Specialist, said the application of PRP around the genital organ promotes blood flow and cell growth which leads to regeneration within the Clitoris. The result is new, healthy tissues (clitoris) that is permanent, he added.

Dr. Ikudayisi decried the high prevalence of female genital mutilation in Nigeria and in many African countries saying that apart from denying women the opportunity of enjoying sex it has huge health implications.

These include abscesses, cysts, excessive scar tissue, painful sex and menstruation, Hepatitis and other blood-borne diseases, urinary tract infections, infertility, and increased risk of bleeding during childbirth.

Ikudayisi said a survey on February 1, 2022, by Statista Research Department, shows that as of 2018, 20 per cent surveyed women in Nigeria had undergone female genital mutilation. Compared to 2013, this figure decreased by five percentage points (25 per cent)..

According to him, Nigeria ranks the third-highest globally in the prevalence of FGM, accounting for 10 per cent of the global total.

Ikudayisi identified age-long cultural and religious practices as the factors promoting FGM in Nigeria.

He said several civil society organisations and international non-governmental organisations are involved in strong advocacy against FGM while those females who have come under the knife can get their genital area, especially the clitoris back, and hence have full sexual experience through the O-Shot therapy.

Like Loading...

Follow this link:
O-Shot Therapy Raises Hope of Enhanced Sexual Experience in Genitally Mutilated Females - THISDAY Newspapers

Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Demand Growth, Geographic Segmentation, Key Players Analysis To 2028 Political…

Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market market research report is always useful to business or organization in many subjects of trade for taking better decisions, solving the toughest business questions, and minimizing the risk of failure. The studies of this market report carefully analyzes the market status, growth rate, future trends, market drivers, opportunities, challenges, risks, entry barriers, sales channels, and distributors. The most advanced tools and techniques including SWOT analysis and Porters Five Forces Analysis have been applied to structure this business report. Moreover, diverse segments of the market are taken into consideration in Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market market report which gives better market insights and extend reach to the success.

The Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Marketthrows light on the major insights that offer the users a comprehensive addition of several factors such as global distribution, market size, manufacturers, and market factors that affect the global contributions. In addition, theEurope Autologous Stem Cell and Non-Stem Cell Based Therapies Market study also shifts its attention of the users with an in-depth competitive landscape, growth opportunities, market share along with product type and applications, key companies active in the market, and growth strategies practiced by the leading players.

Download Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market report also indicates a narrowed decisive summary of the market. Along with this, multiple factors which have affected the advancement and improvement in a positive as well as negative manner are also studied in the report. On the contrary, the various factors which will be acting as the opportunities for the development and growth of the Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market in the forecasted period are also mentioned.

Top Keyplayers in Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report:

Abbott, Takeda Pharmaceutical Company Limited., Cytori Therapeutics Inc., GENERAL ELECTRIC COMPANY, Spiegelberg GmbH & Co. KG., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Endotronix, Inc., among other.

Feel Free To Ask Question Before Purchasing The Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Analysis

Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

What Does The Report Include? The report includes a variety of topics significant for the market players to understand such as financial structure of the market, market size, market threats, constraints, total production, annual sales, yearly revenue, growth prospects, and more about the Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The report includes forecast from the year 2021 and 2028, demand, and expected revenue in US dollars. Macroeconomic indicators influencing theEurope Autologous Stem Cell and Non-Stem Cell Based Therapies Market are provided in the report. Sector-wise analysis of the factors identified in demand side, supply side, external factors, and principal forces that are affecting the Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The total demand of the market segmented by business, consumer, and government is given in the report.

While deciding the strategies regarding production as well as marketing, market drivers and market restraints are very helpful to the businesses. The wide ranging Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market market report also provides predictions about the practical arrangement of suspicions and techniques. While framing this market report, methodical gathering and analysis of information about individuals or organisations has been conducted through social and opinion research. Besides, the individuality of respondents is kept secretly without doing any promotional approach to them while analysing the data of this industry report. Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market market survey report assist in building a strong organization and make better decisions for driving a business on the right track.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Related Reports:

https://www.databridgemarketresearch.com/reports/global-laparoscopic-appliers-market

https://www.databridgemarketresearch.com/reports/global-fluorescent-antibody-test-fat-market

https://www.databridgemarketresearch.com/reports/global-neonatal-jaundice-treatment-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Original post:
Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Demand Growth, Geographic Segmentation, Key Players Analysis To 2028 Political...

Eggschain CEO to Speak on Blockchain Applications in Fertility Treatment at 2022 College of Reproductive Biology Symposium – Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Eggschain, the first biotech company on the bitcoin blockchain and the first patented blockchain-integrated chain of custody and end-to-end lab management solution for all biospecimens, is pleased to share that company founder and CEO Wei Escala will be speaking at the 2022 College of Reproductive Biology (CRB) Symposium. The event will take place May 12 May 14 in Austin, Texas, at the AT&T Hotel and Conference Center.

Details of Ms. Escalas discussion are below: Title: Blockchain and Information Technology Applications in Fertility Treatment Date: Saturday, May 14, 2022 Time: 10:15 a.m. - 11:15 a.m. CT

The CRB Symposium presents an excellent opportunity to educate the scientific community on how our platform can bring professional grade information and data to individuals undergoing fertility treatments in a secure, transparent and universally trackable format, as well as how our platform can apply to other biospecimen procedures, said Wei Escala, founder and CEO of Eggschain. Biospecimens include but are not limited to sperm, eggs, embryos, DNA, RNA, tissues, organs, genome, blood and stem cells, illustrating the broad application of Eggschains patented capabilities."

The College of Reproductive Biology (CRB), a not-for-profit special interest group of the American Association of Bioanalysts (AAB), provides a focused forum for andrologists and embryologists to communicate with each other, share ideas and knowledge, and foster closer collaborations. CRBs educational programs have been well received within the field of assisted reproductive technology by clinic staff and laboratory personnel. The CRB Symposium educational program features a variety of topics covering the newest science and technology and is approved for continuing education credit. Symposium attendees are reproductive biologists and include laboratory directors, technical supervisors, clinical consultants, and andrology and embryology laboratory scientists.

About Eggschain, INC. Eggschain is a healthcare technology company and thought leader in the fertility, health tech, family-building and cryogenic preservation industries. Patent-granted and cloud-based, Eggschain is the first blockchain-integrated inventory management and chain of custody technology for tracking bio specimens, including sperm, eggs, embryos, genome, stem cell, tissues and organs, and other genetic material. In partnership with several of the worlds leading experts in reproductive biology, endocrinology and high complexity labs, Eggschain delivers medical grade information and data to individuals undergoing IVF in a secure, transparent and universally trackable format and also provides the means for clinics to monitor their inventory, either personal, such as oocytes and sperm, or lab-related, including equipment inventory and maintenance scheduling. At its core, Eggschain strives to enable better decision-making, preserving the hope of life and helping to advance humanity.

About AAB The American Association of Bioanalysts (AAB) is a professional association representing bioanalysts (clinical laboratory directors, owners, managers, and supervisors), medical technologists, medical laboratory technicians, and physician office laboratory technicians. AABs specialized membership sections include the College of Reproductive Biology (CRB), AAB Associate Member Section (AMS), Environmental Biology and Public Health (EBPH) Section, and the National Independent Laboratory Association (NILA).

Read more from the original source:
Eggschain CEO to Speak on Blockchain Applications in Fertility Treatment at 2022 College of Reproductive Biology Symposium - Business Wire

Drug Price Watchdog Calls Bluebird Bio’s $2.1 Million Gene Therapy Cost-Effective – BioSpace

Courtesy of Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

Drug pricing watchdog ICER, the Institute for Clinical and Economic Review, issued a draft report on bluebird bios gene therapy betibeglogene autotemcel for beta-thalassemia. Despite the proposed price tag of $2.1 million, ICERs not-yet-finalized report supports the therapys cost-effectiveness. This is good news for the recently beleaguered company.

Gene therapies are typically designed to cure a disease by replacing or fixing a damaged gene. Bluebirds therapy, which is listed under the brand name Zynteglo, had been approved in Europe and the UK, where its price is around $1.7 million (U.S.). However, the company pulled the therapy off the market in Europe over what it called a hostile pricing and reimbursement environment.

On April 5, bluebird bio announced it was beginning a comprehensive restructuring in hopes of cutting $160 million in costs over the next two years. It planned to re-focus on near-term catalysts, which include Zynteglo in the U.S., gene therapy for cerebral adrenoleukodystrophy (eli-cel) and a potential biologics license application (BLA) for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease. The BLA application is planned for 2023, while the U.S. regulatory decisions are expected this year. The PDUFA date for Zynteglo is Aug.19, 2022, and Sept. 16, 2022, for eli-cel.

As part of the restructuring, the company is cutting its workforce by about 30%.

ICER recommendations arent binding, but they have influence. If ICER says a drug is overpriced, it provides ammunition for payers, such as Medicare and insurers, to push back against proposed prices.

Gene therapies are very expensive. For example,Novartis Zolgensma, the one-time gene therapy onasemnogene abeparvovec for spinal muscular atrophy (SMA), is generally viewed as the most expensive drug with a price tag of $2.1 million. On the other hand, as an apparent cure for a disease that kills children by the age of two, it is very rare. The argument for these therapies, aside from their curative potential for otherwise incurable diseases, is that over the life of the patient, they are cost-effective.

Novartis and Spark Therapeuticss gene therapy Luxturna (voretigene neparvovec) runs about $850,000 per patient in the U.S. The therapy is for inherited retinal dystrophy with RPE65 mutations. It is typically diagnosed in childhood and eventually causes almost total blindness, and the therapy is essentially a cure.

Beta thalassemia is a genetic disease that impairs the ability of red blood cells to manufacture hemoglobin, the molecule in the body that carries oxygen. There are about 40,000 newly diagnosed cases in children each year around the world. People with the most severe form of it develop life-threatening anemia around four to six months of age and have to receive monthly blood transfusions and other treatments, such as iron-chelating drugs. The only other potential cure is hematopoietic stem cell transplantation (HSCT) but requires a donor with a matching human leukocyte antigen (HLA) profile within the appropriate age range.

Bluebirds Zynteglo appears to be another option for a cure, although how long the therapys effects last is something of an open question. The ICER report noted the uncertainties, but concluded that the evidence suggests that beti-cel provides net health benefits to patients with TDT.

The ICER report indicated, per Managed Healthcare Executive, that "patients could be treated without reaching the potential budget impact threshold at three prices (about $1.85 million, $2.11 million and $2.38 million per course of treatment). This analysis was done at several prices to document the percentage of patients who could be treated without crossing a potential budget impact threshold that is aligned with the overall growth in the U.S. economy.

In Phase III trials, 89% of patients who received the therapy became transfusion independent, and in Phase I/II and III trials, those patients remained transfusion-free for at least 42 months. In general, side effects were mild and no deaths were reported. In December 2021, bluebird presented data at the American Society of Hematology meeting from a long-term study (LTF-303) that showed adult and pediatric patients with beta-thalassemia who required regular red blood cell transfusions can produce normal or near-normal levels of total hemoglobin and remain transfusion-free with stable iron markers up to seven years after receiving beti-cel.

A 2017 study published in Blood found that on average, beta-thalassemia patients required 17 transfusions per year, 23 days apart. Mean total healthcare costs for the patients were $128,062, plus or minus $62,260 per year. Total costs were primarily driven by chelation and transfusion costs.

Although the severity of the disease varies, a 2009 study found that people with beta-thalassemia major often die from cardiac complications of iron overload by 30 years of age," making bluebird's new therapy, if it is successful, vital for these patients.

Continue reading here:
Drug Price Watchdog Calls Bluebird Bio's $2.1 Million Gene Therapy Cost-Effective - BioSpace

Spotlight:Seeing is believing! Safe & effective treatments for dark circles and eye wrinkles – CambridgeToday

ArtMed's Medical Director, Dr. Peirson discusses scientifically researched and safe cosmetic eye treatments and why you should consider PRP instead of dermal fillers.

Do you feel like your eyes are prematurely aging you? Dark under-eye circles? Hollow and looking tired all the time? Wrinkles and crepiness?

These are among the most common complaints and inquiries received at a medical aesthetics clinic. Dark circles and hollows are frustrating because they tend to suggest an individual is tired, sad, recovering from illness or a night out on the town.

There are a number of ways to address under eye concerns, but no single cream or treatment is a cure all. Nonetheless, some treatments are more effective, safer and long lasting than others.

Historically, the go-to treatment for under eye circles and hollows has been dermal fillers. Hyaluronic acid dermal fillers (a type of sugar gel) can be injected under the eye to fill hollows and lift the skin improving the appearance of dark circles.

However, there are issues with dermal fillers. Fillers can lead to:

In recent years, research has shown that PRP injections are a safer and more natural option for treating the delicate eye area. PRP or platelet rich plasma, is blood plasma that has been specially prepared to maximize the platelet content. Platelets, are clotting factors that bind together at the site of an injury to stop bleeding. Most importantly, platelets initiate the healing process by releasing growth factors and promoting new blood vessel formation. This results in new tissue generation, including collagen, elastin and fibrin (CEF) production.

Collagen is a protein fibre produced by skin cells that increases skin thickness and density. Elastin provides stretchability to skin and fibrin is the support structure or scaffold around which collagen and fibrin grow.

PRP has been used for decades to treat wounds, surgical sites, burns, sports injuries and more. In recent years PRP has been used in aesthetics to speed wound healing after laser procedures and as an injectable to promote CEF production to revitalize aging and thinning skin of the eye area, neck and chest, elbows, knees and more. PRP can even be used to create eye drops for chronic dry eye.

PRP treatments involve blood being drawn from the patient, and then spun and separated to obtain PRP which is then immediately injected into the treatment area. For the eye area, a series of 3 treatments is typically recommended about 4-6 weeks apart. Bruising is common as is swelling in the firs 24-48 hours.

PRP stimulates the thin skin of the under eye to start producing CEF which leads to firmer, thicker more elastic skin and a reduction in wrinkles. PRP stimulates new blood vessel growth thereby improving blood flow and luminosity to the area and may reduce puffiness for some. Dark circles are improved because thicker skin decreases the visibility of dark blood vessels below.

In other words, out with the old, in with the new! PRP revitalizes the thin skin of the eye area. Unlike fillers which are purely symptomatic treatment (and not without complications), PRP renews and maintains the delicate skin of the eye area naturally and safely.

In addition to PRP consider the following:

Since 80% of visible aging is caused by the sun, a daily application of mineral sunblock appropriate for the eye is essential. Stick sunscreens have thicker formulas so they stay put avoiding migration into the eye. Some makeup concealers contain mineral sunblock thereby providing a two-for-one benefit. UVA/UVB blocking sunglasses are an under-appreciated tool in preventing aging around the eye.

Finally, its important to restate that PRP treatments are entirely natural. Because it is your own blood derived PRP theres virtually no risk of adverse side effects or issues down the road. Results can be maintained with 1 or 2 treatments a year.

To learn more,visitartmed.caor emailinfo@artmed.ca.

Link:
Spotlight:Seeing is believing! Safe & effective treatments for dark circles and eye wrinkles - CambridgeToday

We Are Taking it to the Next Level Valencia Medical Center is Now Offering Regenerative & Aesthetic Medicine Training To Physicians & Medical…

Valencia Medical Center is one of the pioneer centers in Regenerative Medicine and PRP (Platelet-Rich Plasma) Therapy for the following: Joint pain injuries of knee, shoulder & elbow Osteoarthritis and inflammation Our highly concentrated PRP injections guided by ULTRASOUND IMAGING with needle recognition capability, has given our patients an opportunity to enjoy life pain-free We are also offering advanced PRP Hair restoration, PRP Penile shot and Acoustic Wave Therapy for Erectile Dysfunction (ED) High success rate and patients satisfaction along with weekly Live at Five with our doctor on our social media accounts, has won us patients loyalty. Due to high demand and our expertise in the advancement in the field of regenerative medicine, Valencia Medical Center & Ageless Life Institute is providing Regenerative & Aesthetic Medicine training for the medical community & physicians on March 18-19, 2022. Please see our announcement in this issue. For more information, please contact us at 661-222-9117

Go here to see the original:
We Are Taking it to the Next Level Valencia Medical Center is Now Offering Regenerative & Aesthetic Medicine Training To Physicians & Medical...

Survey finds nearly 1 in 5 Americans experience pain with exercise and continue to work out rather than resting to heal – EurekAlert

Addressing injuries early make them easier to treat with effective non-surgical options

video:Millions of people are dealing with a lingering injury or nagging pain, maybe from a bad knee or a sore elbow. In fact, a new national survey for Orlando Health finds nearly one in five Americans often experience pain when working out and the same number of people work through the pain rather than resting to heal. view more

Credit: Orlando Health Jewett Orthopedic Institute

Orlando, Fla Its not uncommon to have a lingering injury or nagging pain. In fact, a new national survey by Orlando Health finds nearly one in five Americans (18%) often experience pain while working out and the same number of people (18%) work through the pain rather than resting to heal.

Sports medicine physicians and orthopedic surgeons at the Orlando Health Jewett Orthopedic Institute say identifying the source of pain is the first step toward feeling better, and new advancements offer a range of options before surgery is part of the discussion. However, delaying treatment often leads to further damage and a higher likelihood that surgery will be needed to repair it.

There's the saying, No pain, no gain. But there's different types of pain that you feel during workouts, and sharp, stabbing pain that's very uncomfortable is not typically normal, said George Eldayrie, MD, a sports medicine physician at Orlando Health Jewett Orthopedic Institute. The pain may be coming from an underlying problem and if you continue to push through it you can make that problem worse.

Non-surgical options may include physical therapy to stretch and strengthen specific muscles and tendons. It may also involve injections that reduce inflammation and promote healing, such as corticosteroids and platelet-rich plasma, which are delivered precisely to the right area using ultrasound technology.

Rehabilitation is a powerful tool, but its important to see a professional who can really key in on the right diagnosis so a therapist can develop a treatment plan focused to the right area, saiid Dr. Eldayrie. Platelet-rich plasma has also been shown to be very effective for chronic tendinopathies, things like tennis elbow or golfers elbow. But it typically works better the earlier it is administered, before the injury progresses.

Jen Jordon, 39, lived with increasing pain in her left knee for years before finally making an appointment with Dr. Eldayrie to address it.

I would go into a lunge and just feel a sharp pain and then it would just continuously hurt throughout the day, said Jordon. It just kept getting a little bit worse and affecting me a little bit more during workouts and while I was on my feet at work, so I decided it was time to go get it checked out.

Exercise is a daily part of Jordons life and something she relies on to maintain her physical and mental health. She put off treatment for fear she would be sidelined for a long period of time, or worse, would be told she needed surgery.

Surgery is definitely a fear of mine. One of the reasons I work out is to stay healthy and prevent the need for surgery as I get older, Jordon said. Part of me didn't really want to know what was going on because I didn't want to have to take time off or have a procedure that was going to take weeks or months of recovery.

Dr. Eldayrie examined Jens knee using x-rays and ultrasound to show her in real time where her tendons were strained and where degradation was occurring.

He was able to just point to the affected area and show me exactly what the issue was on his tablet. It was really informational and empowering to see the problem and learn how to take action to fix it, Jordan said.

Jen was also relieved to learn that she does not need surgery at this time, and will likely be able to solve her knee pain by adding exercises to better support the affected area. This will not only heal her knee, but also her fear of dealing with injuries.

I am so glad that I went and had Dr. Eldayrie look at it, and I think it will help me prevent anything worse from happening in the future, said Jordon. After suffering for so many years and learning that simple stretching could have prevented the pain for all this time, I will definitely go in as soon as something starts hurting next time.

While there are a lot of non-surgical options, surgery is often the best course of action for injuries that require repair or reconstruction and will not heal on their own. However, that is not as scary as many patients believe. Advancements in robotic and laparoscopic procedures have made many surgeries less invasive and recovery shorter and easier than ever.

B-ROLL, SOUND BITES, WEB ELEMENTS & HI-RES STILL PHOTOS - Including HD video available for free/unrestricted use by the news media: https://bit.ly/3itF1nY Courtesy: Orlando Health Jewett Orthopedic Institute *Password: ortho (by entering the password, you agree to honor the embargo)

For assistance in downloading, or if you have any questions, contact: ben@mediasourcetv.com or call: 614.932.9950.

Survey Method: This survey was conducted online within the United States by The Harris Poll on behalf of Orlando Health from February 22 - 24, 2022 among 2,077 adults ages 18 and older. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact ben@mediasourcetv.com.

ABOUT ORLANDO HEALTH Orlando Health, headquartered in Orlando, Florida, is a not-for-profit healthcare organization with $7.6 billion of assets under management that serves the southeastern United States.Founded more than 100 years ago, the healthcare system is recognized around the world for its pediatric and adult Level One Trauma program as well as the only state-accredited Level Two Adult Trauma Center in the St. Petersburg region. It is the home of the nations largest neonatal intensive care unit under one roof, the only system in the southeast to offer open fetal surgery to repair the most severe forms of spina bifida, the site of an Olympic athlete training facility and operator of one of the largest and highest performing clinically integrated networks in the region. Orlando Health has pioneered life-changing medical research and its Graduate Medical Education program hosts more than 350 residents and fellows. The 3,200-bed system includes 16 wholly-owned hospitals and emergency departments; rehabilitation services, cancer and heart institutes, imaging and laboratory services, wound care centers, physician offices for adults and pediatrics, skilled nursing facilities, an in-patient behavioral health facility, home healthcare services in partnership with LHC Group, and urgent care centers in partnership with FastMed Urgent Care. Nearly 4,500 physicians, representing more than 90 medical specialties and subspecialties have privileges across the Orlando Health system, which employs more than 23,000 team members. In FY21, Orlando Health served nearly 160,000 inpatients and nearly 3.6 million outpatients. During that same time period, Orlando Health provided approximately $648 million in total value to the communities it serves in the form of charity care, community benefit programs and services, community building activities and more. Additional information can be found at http://www.orlandohealth.com, or follow us on LinkedIn, Facebook, Instagram and Twitter @orlandohealth.

Visit link:
Survey finds nearly 1 in 5 Americans experience pain with exercise and continue to work out rather than resting to heal - EurekAlert

Dont live with chronic pain – The New Indian Express

By Express News Service

KOCHI:Chronic pain is any pain that lasts more than three months. It may persist for years sometimes, affecting a persons ability to work or sleep well. This could lead to social isolation and often precipitate financial distress. Chronic pain can badly impact the quality of life of a person.

But chronic pain requires a separate speciality. Acute pain (especially those following trauma) has specific underlying causes that can be easily identified and treated. Chronic pain, on the other hand, irrespective of the underlying cause, induces many changes in our nervous system. Over time, the pain becomes even more complex and difficult to treat and causes psychological issues like anxiety and depression. Eventually, it metamorphoses into a disease.

The emergence of pain medicine as a speciality was born out of the need to have a holistic approach dedicated to the diagnosis and management of such pain. Chronic pain can have a variety of underlying causes. Identification of the structure that produces pain is the first step, followed by amelioration and prevention of recurrence.

Following are some relevant questions on pain medicine

How can you benefit from consulting a pain management specialist? Management of chronic pain, irrespective of the cause, can benefit from a multi-disciplinary method. The most common pain-related chronic condition are those that affect the musculoskeletal system back, neck, knee or shoulder. Other conditions are facial (trigeminal neuralgia), chronic abdominal or pelvic, and cancer pains. A visit to a specialist could give you more insights into all these.

What are the services offered by a pain specialist? Pain is subjective, and very often healthcare workers or the patients caregivers tend to blame the patients stress or anxiety for it when everything else (blood investigations, MRI) look normal. Pain generators can produce disabling pain, but may not be visible in any of the investigations.

A pain specialist begins by believing the patient when they say they are in pain. This is very important. The next step is to identify the pain generator. A detailed clinical evaluation is key to identifying the root cause of pain. Blood investigations, X-ray or other imaging modalities may be employed. A specialist will also look for signs of underlying pathology, like tumours, fractures or infections. Such patients are referred to doctors who can take better care of the condition.

Afterwards, an individualised treatment plan depending on the age of the patient, cause and severity of pain, and comorbidities is formulated.

What are the treatments offered by a pain clinic? We often start by optimising medicines and physiotherapy. Pain killers or analgesics may be employed for a short while but not as a long-term solution.

Chronic pain induces changes in our nervous system. Over time, nerves that transmit pain sensations become hypersensitive. Pain modulators or neuromodulators are used to desensitise these nerves. These drugs are safer for long-term use. We also advise patients to do stretching exercises and physiotherapy. If a patient does not benefit from medical management and physiotherapy, minimally invasive interventions (injections) are used. X-ray or Ultrasound-guided injections targeting the pain generator have an important role in establishing the correct diagnosis as well as in the management of pain.

Commonly performed injections include nerve blocks, injection of local anaesthetics with or without steroids, injection of platelet-rich plasma, joint injections, myofascial injections and radiofrequency ablation of nerves.

Are these injections expensive? Do they have side effects? All interventions are done with the help of image guidance either X-ray or Ultrasound. This improves the accuracy of the procedure and makes them very safe. Serious adverse effects are exceedingly rare. The cost of the procedure depends on the type of injection. Simple nerve blocks, myofascial or joint injections are not expensive. Newer treatment modalities like radiofrequency ablation involve the use of an RF device and are therefore slightly more expensive.

How long will the patient be pain-free after the interventions? This depends on the cause of pain and the type of injection. Certain injections, like a transforaminal epidural injection for back pain or sciatica, usually gives pain relief for up to an ear. Radiofrequency ablation of nerves can give pain relief lasting more than a year. However, certain other interventions like joint injections may be more short-lived. Their benefits may last only up to three months. However, interventions often provide immediate and excellent pain relief, which helps the patients do stretching or strengthening exercises more efficiently. This also contributes to the efficacy of the medical management and provide sustained pain relief without recurrence of severe disabling pain.

Will all chronic pain patients benefit from interventions? No, interventions are helpful when the pain generator can be identified and blocked. In certain chronic pain conditions, interventions may not be possible. In other cases, the patient may not be willing to get an injection. In that scenario, we proceed to modify the procedure.

What are the challenges in dealing with chronic pain patients? The suffering in chronic pain makes patients extremely anxious, distressed and frustrated. This results in poor treatment compliance. Pain prevents them from doing exercises and with time, muscles, bones and joints become de-conditioned causing more pain. One has to realise that the pain which has been present for months or years, causes sensitization of the nervous system and de-conditioning of the musculoskeletal system. A multi-modal management strategy targeting not just the pain generator, but all these components can provide significant pain relief.

The author is a consultant in the Department of Pain Medicine at KIMSHEALTH

See the rest here:
Dont live with chronic pain - The New Indian Express

Penn researchers discover new cell type in human lung with regenerative properties – EurekAlert

Findings shine light on underpinnings of COPD, pave new direction for future research on treatments

image:Human ES cell derived RASC (respiratory airway secretory cell transitioning to an Alveolar type 2 cell over time in culture view more

Credit: Penn Medicine

PHILADELPHIA A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.

The researchers, who report their findings today in Nature, analyzed human lung tissue to identify the new cells, which they call respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that RASCs have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of RASCshinting that correcting this disruption could be a good way to treat COPD.

COPD is a devastating and common disease, yet we really dont understand the cellular biology of why or how some patients develop it. Identifying new cell types, in particular new progenitor cells, that are injured in COPD could really accelerate the development of new treatments, said study first author Maria Basil, MD, PhD, an instructor of Pulmonary Medicine.

COPD typically features progressive damage to and loss of alveoli, exacerbated by chronic inflammation. It is estimated to affect approximately 10 percent of people in some parts of the United States and causes about 3 million deaths every year around the world. Patients often are prescribed steroid anti-inflammatory drugs and/or oxygen therapy, but these treatments can only slow the disease process rather than stop or reverse it. Progress in understanding COPD has been gradual in part because micethe standard lab animalhave lungs that lack key features of human lungs.

In the new study, Morrisey and his team uncovered evidence of RASCs while examining gene-activity signatures of lung cells sampled from healthy human donors. They soon recognized that RASCs, which dont exist in mouse lungs, are secretory cells that reside near alveoli and produce proteins needed for the fluid lining of the airway.

With studies like this were starting to get a sense, at the cell-biology level, of what is really happening in this very prevalent disease, said senior author Edward Morrisey, PhD, the Robinette Foundation Professor of Medicine, a professor of Cell and Developmental Biology, and director of the Penn-CHOP Lung Biology Institute at Penn Medicine.

Observations of gene-activity similarities between RASCs and an important progenitor cell in alveoli called AT2 cells led the team to a further discovery: RASCs, in addition to their secretory function, serve as predecessors for AT2 cellsregenerating them to maintain the AT2 population and keep alveoli healthy.

AT2 cells are known to become abnormal in COPD and other lung diseases, and the researchers found evidence that defects in RASCs might be an upstream cause of those abnormalities. In lung tissue from people with COPD, as well as from people without COPD who have a history of smoking, they observed many AT2 cells that were altered in a way that hinted at a faulty RASC-to-AT2 transformation.

More research is needed, Morrisey said, but the findings point to the possibility of future COPD treatments that work by restoring the normal RASC-to-AT2 differentiation processor even by replenishing the normal RASC population in damaged lungs.

The research was supported by the National Institutes of Health (HL148857, HL087825, HL134745, HL132999, 5T32HL007586-35, 5R03HL135227-02, K23 HL121406, K08 HL150226, DK047967, HL152960, R35HL135816, P30DK072482, U01HL152978), the BREATH Consortium/Longfunds of the Netherlands, the Parker B. Francis Foundation, and GlaxoSmithKline.

###

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $8.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.

Cells

Human distal airways contain a multipotent secretory cell that can regenerate alveoli

30-Mar-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the rest here:
Penn researchers discover new cell type in human lung with regenerative properties - EurekAlert

Bridging or perpeatuating health inequities? ScienceDaily – Verve Times

Health inequities among Black Indigenous People of Color, immigrant and low-income communities is driven largely by inadequate healthcare access. Telehealth offers an opportunity to increase healthcare access and reduce health inequities. However, according to researchers from Boston University Questrom School of Business, Boston University School of Medicine (BUSM), and Boston Medical Center (BMC), telehealth has unwittingly become a double-edged sword, whereby the technology with potential to reduce health inequities also holds the key to exacerbate structural inequities.

Using qualitative data and our own experiences as front line primary care physicians we discovered that while digital access is necessary, it is not sufficient in redressing disparate engagement with telehealth, says corresponding author Rebecca G. Mishuris, MD, MPH, MS, assistant professor of medicine at BUSM, and primary care physician and Chief Medical Information Officer of the BMC Health System.

According to the researchers, a key component of these structural inequities is the digital divide, driven partly by digital redlining. Digital redlining is the modern day manifestation of redlining that perpetuates health inequities and structural racism by maintaining barriers to technological access, further perpetuating lack of healthcare access.

Based on their experience as well as data about their patients access to healthcare, virtual and otherwise, Mishuris and her colleagues theorize that two additional barriers to equitable telehealth exist: digital fluency, the ability to use digital tools efficiently and effectively; and the capacity for health advocacy, a patients ability to advocate for their own health needs.

Without addressing these critical, less often discussed elements of telehealth implementation, it is our belief that telehealth will fall short of its promise and rather than mitigate health inequities, will perpetuate health inequities in the very communities that stand to benefit most from its implementation, says co-author Katherine Gergen Barnett, MD, clinical associate professor of family medicine at BUSM and Vice Chair of Primary Care Innovation and Transformation at BMC.

In an effort to overcome the barriers of device and broadband access, digital fluency and health advocacy to mitigate current inequities in digital health engagement, the researchers propose a three-pronged approach of creating federal and state policies to democratize access to telehealth. By establishing platform standards for accessing telehealth, and supporting societal and health system investments to increase health literacy, advocacy and technology fluency, we can begin to address the disparities in telehealth engagement and healthcare access, says Mishuris.

Collaborators include Jayakanth Srinivasan, PhD, research associate professor at Boston Universitys Questrom School of Business; Charles T. Williams, MD, BMC/BUSM family medicine; Alexa Bragg, BS, BMC/BUSM family medicine; Afi M. Semenya, MD, MPH, BMC/BUSM family medicine; Marielle Baldwin, MD, MPH, BMC/BUSM family medicine; Jessica Howard, MA, MPH, BMC/BUSM family medicine and Stephen A. Wilson, MD, MPH, BMC/BUSM family medicine.

These findings appear as a Perspective in the Journal of General Internal Medicine.

Funding was provided by the Boston University Center for Antiracist Research.

See original here:
Bridging or perpeatuating health inequities? ScienceDaily - Verve Times